Clinical Trials Logo

Clinical Trial Summary

The aim of this study To compare the clinical and laboratory outcomes of two ovarian stimulation protocols (standard GnRH antagonist protocol and aromatase inhibitor/ antagonist protocol) in women (40-44) years undergoing ICSI cycle.


Clinical Trial Description

Fertility is known to decline significantly in women after the age of 35 years, and fecundity is almost completely lost after the age of 45 . As age increases the natural fecundity and pregnancy rates after assisted reproduction decrease .This reduction in fecundity is thought to be due to ovarian aging mainly, which is defined as a decline in both the quantity and quality of the ovarian follicle pool .The increase in patient's age is associated with poor ovarian response, as represented by smaller ovarian volume, lower antral follicle count and poor stromal vascularity. In addition to the reduction in fecundity, there is an increase in spontaneous abortion rates in this group of women .It has been reported that about 19% of all women undergo ART are 40 years, and they could be considered as expected poor responders .Various protocols of ovarian stimulation have been proposed to optimize IVF results in this age group, however, satisfactory results remain a challenge . The lack of initial central down-regulation in early follicular phase and adequate prevention of premature luteinizing hormone (LH) surge in late follicular phase provide GnRH antagonist protocol as a potentially proper option .The use of aromatase inhibitors in a GnRH antagonist protocol was suggested by some studies [Mit. Yarali and colleagues demonstrated that adjuvant therapy with letrozole could improve the response [Yarali et al., 2009]. Meanwhile, in another study, adding letrozole to ovarian stimulation has no positive effect on the likelihood of pregnancy . Letrozole is a selective, non-steroidal third generation aromatase inhibitor. Letrozole causes a reduction in conversion of androstenedione and testosterone to estrone and estradiol by inhibiting the aromatase enzyme activity . According to some published studies, the decline in early follicular phase estrogen levels, and consequently decrease in negative feedback of estrogen on FSH release in hypothalamic-pituitary axis cause an increase in endogenous gonadotropin secretion and stimulation of ovarian follicular growth. In addition, an increase in intraovarian androgens secondary to aromatase inhibition, augments the follicular sensitivity to FSH stimulation and follicular growth . Letrozole has no antiestrogenic effect over the endometrium . These reports prompted us to hypothesize that use of letrozole as a co-treatment agent in GnRH antagonist protocol might enhance cycle outcomes. I ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05166668
Study type Interventional
Source Menoufia University
Contact
Status Recruiting
Phase N/A
Start date November 1, 2021
Completion date December 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT01121991 - A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies Phase 3
Not yet recruiting NCT04539067 - Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo Phase 2
Recruiting NCT02715336 - Efficacy and Safety of Medication Used to Stimulate Ovulation Phase 4
Not yet recruiting NCT03298750 - Mechanical Stimulation of the Ovary for Infertility Treatment in Patients With Very Low Ovarian Reserve N/A
Completed NCT03939403 - Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor Phase 4
Recruiting NCT06142708 - The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger N/A
Completed NCT04549649 - The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response N/A
Terminated NCT01816789 - Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles Phase 4
Completed NCT00823004 - Antagonist/Letrozole in Poor Responders Phase 1/Phase 2
Not yet recruiting NCT06175832 - PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study Phase 4
Completed NCT00830492 - Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist Phase 4
Completed NCT01145144 - Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment N/A
Completed NCT00829075 - Impact of Three Different Gonadotrophin Regimes on Egg Donation Program Phase 4
Completed NCT01037699 - Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles Phase 3
Completed NCT01112358 - Lutropin Alfa in Women at Risk of Poor Response Phase 2
Recruiting NCT03400722 - Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response Phase 4
Completed NCT00669786 - Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles Phase 3